Research_

# Surveys

Surveys are a valuable method of data collection, and are incredibly useful in providing snapshots of information via questions put to a community.
We have conducted a variety of surveys that have shed light on various aspects of medical cannabis in Australia, covering both general practitioners and patients.

### Our Research

This survey aims to understand gastrointestinal specialist experiences and perceptions of medicinal cannabis for inflammatory bowel disease to inform policy decisions, assist in development of educational material to meet the specific needs of specialists and inform interest in participating in our clinical research.

Chief Investigator: Professor Iain McGregor (The Lambert Initiative, University of Sydney)

Project Coordinator: Doctor Melissa Benson (The Lambert Initiative, University of Sydney)

Collaborators: Associate Professor Susan Connor (Liverpool Hospital) and Doctor Crispin Corte (Royal Prince Alfred Hospital)

This nationwide online survey is being conducted by researchers at the University of Sydney’s Lambert Initiative for Cannabinoid Therapeutics. It aims to understand the perspectives of IBD patients who currently use, have previously used or have never used cannabis products to manage their IBD symptoms, helping to inform future clinical trials with cannabis-based therapies.

Chief Investigator: Professor Iain McGregor (The Lambert Initiative, University of Sydney)

Project Coordinator: Doctor Melissa Benson (The Lambert Initiative, University of Sydney)

Collaborators: Associate Professor Susan Connor (Liverpool Hospital) and Doctor Crispin Corte (Royal Prince Alfred Hospital)

Publication: https://bmjopen.bmj.com/content/8/7/e022101

A cross-sectional survey completed by 640 Australian General Practioners attending multiple-topic educational seminars in five major Australian cities between August and November 2017 was undertaken to assess the knowledge and attitudes of these clinicians toward medicinal cannabis.

Results: The majority of GPs (61.5%) reported one or more patient enquiries about medicinal cannabis in the past three months. Most felt that their own knowledge was inadequate and only 28.8% felt comfortable discussing medicinal cannabis with patients. Over half (56.5%) supported availability on prescription, with the preferred access model involving trained GPs prescribing independently of specialists. Support for use of medical cannabis was condition-specific, with strong support for use in cancer pain, palliative care and epilepsy, and much lower support for use in depression and anxiety.

This was a collaboration between The Lambert Initiative at the University of Sydney and HealthEd.

Chief Investigator: Professor Iain McGregor (Lambert Initiative, University of Sydney)

Project Coordinator: Dr Emily Karanges & Anastasia Suraev (Lambert Initiative, University of Sydney)

An online survey was developed by Epilepsy Action Australia (EAA), consisting of 39 questions that measured demographic factors, clinical factors (such as diagnosis and seizure types), past treatment history for epilepsy, and experiences and opinions of cannabis use in epilepsy. Results were analysed, interpreted and written up for publication with assistance from Lambert Initiative researchers.

Results: The survey was answered by 976 Australians with epilepsy. It found that 14 percent of people with epilepsy have used cannabis products as a way to manage their seizures. Of these, 90 percent of adults with epilepsy and 71 percent of parents or guardians of children with epilepsy, reported success in seizure management.

This is a collaboration between The Lambert Initiative at the University of Sydney and Epilepsy Action Australia.

Chief Investigator: Professor Iain McGregor (Lambert Initiative, University of Sydney)

Project Coordinator: Anastasia Suraev (The Lambert Initiative, University of Sydney)

The CAMS (Cannabis As Medicine Survey) is the first large scale survey of medicinal cannabis users in Australia for more than a decade. The objective of this survey is to create a national snapshot of the demographics of medical cannabis consumers, the conditions being treated, patterns of cannabis use, perceived efficacy, and the physical and mental health of consumers.

In 2016, the CAMS study surveyed 1,749 Australians who reported using cannabis for medicinal purposes.

Results: Results indicated that the primary conditions being treated included anxiety (50.2%), back pain (49.4%), depression (48.8%), and sleep conditions (43%). Inhaled route was the most common routes of administration. A third of patients spent $0-$50 on cannabis, suggesting a sizeable proportion of home grown supply. Respondents self-reported overwhelmingly positive changes in the primary health condition being treated as a result of cannabis use, with more than 90 percent of respondents reporting an improvement.

This was a collaboration between The Lambert Initiative at the University of Sydney and South East Sydney Local Health District.

Chief Investigator: Professor Nick Lintzeris (South East Sydney Local Health District)

Project Coordinator: Associate Professor David Allsop (The Lambert Initiative, University of Sydney)

This survey builds on the findings of CAMS16. It aims to understand the changing patterns of illicit medical cannabis use in Australia.